Abstract:Monoclonal antibodies are of great use in research and clinic. The first monoclonal antibody production method, hybridoma technology, was marked in the paper "Continuous cultures of fused cells secreting antibody of predefined specificity" by Milstein and Kohler in 1975 in Nature. Based on that paper, we took a retrospective and forward look of this technique. In the early research of antibodies and B cells, the low specificity and bad reproductivity of polyclonal antibodies called for new methods to produce highly specific antibodies. Fortunately, the scientists encountered the key prerequisites of the hybridoma method: (1) Mouse multiple myeloma cell lines, which can secrete antibodies and infinitely reproduce in vitro; (2) SRBC (sheep red blood cell) plates that can screen the cells secreteing anti-SRBC antibodies; (3) proper cell fusion methods like Sendai virus and PEG. Based on all these materials and methods, Milstein and Kohler fused spleen cells of immunized mice with mouse myeloma cell line P3-X67Ag8 by inactivated Sendai virus and screened to clone the fused cells that can secrete anti-SRBC antibodies. They also used HAT medium to ensure that only fused cells from spleen cells and myeloma cells can survive. In this way, they obtained the immortal cells that can produce a single type of antibody with a predefined antigen-specificity, or say, hybridoma cells that can produce monoclonal antibodies. This powerful tool of hybridoma was quickly applied and improved. Milstein and Kohler were awarded the Nobel prize and Lasker award in 1984. Despite the great commercial potential of hybridoma in medication and science research, Milstein and Kohler did not patent the method, making it free to use by anyone in the world. The monoclonal antibodies produced by hybridoma were proved highly versatile in the laboratory. Besides great insights provided to us in basic immunology research, they become the indispensable tool to precisely qualify, quantify, and localize macromolecule in all fields of research. Fluorescence imaging, Western blotting, flow cytometry and microarray methods all make use of monoclonal antibodies. Upon chimera, humanized and human monoclonal antibody development, the application and success of monoclonal antibodies on the biopharma market are even greater. Monoclonal antibody medicines to treat cancer and autoimmune diseases are making billions of dollars every year. Notably, among these medicines, anti-PD-1 and anti-CTLA-4 are awarded Nobel prize in 2018 as anti-tumor immune checkpoint inhibitors. Monoclonal antibody medicines for contagious diseases like Ebola also shows advantages over others. For the new outbreak of COVID-19 around the world, monoclonal antibodies are also promising in offering new cures. Presently, the production of monoclonal antibodies is no longer solely dependent on hybridoma technology. Transgenic and recombinant DNA technology are creating new possibilities in this ever-growing field.

The Monoclonal Antibody Used in the Therapy of Uveitis

[The Function and Changes of Immune Cells in Autoimmune Uveitis].

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Advances in the Study of Antibody Drugs

Monoclonal Antibodies for the Treatment of Ocular Diseases

Progress in Anti-Cd20 Monoclonal Antibodies and Their Clinical Application

Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies

Monoclonal antibodies in the treatment of autoimmune diseases Anticuerpos monoclo-nales en el tratamien-to de enfermedades autoinmunes

Rabbit Monoclonal Antibody: Potential Application in Cancer Therapy

Monoclonal Antibody Drugs for the Treatment of Hematological Malignancies

Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy

[Research Update of Anti-Tnf-α Biologic Agents in the Treatment of Uveitis].

Single-Cell transcriptomes of immune cells provide insights into the therapeutic effects of mycophenolate mofetil on autoimmune uveitis

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases

Monoclonal antibodies in treatment of myasthenia gravis

Application of Monoclonal Antibody in Diagnosis of Animal Disease

Recent advances in treatment of experimental autoimmune uveoretinitis

Progress in Systemic Treatments of Non-Infectious Uveitis

Basic Studies of Monoclonal Antibodies for Therapy

Monoclonal Antibodies: Emergence, Present and Outlook